Table 3.
Median and range of pretreatment (T0) levels of plasmatic ICs in all mccRCC patients and in long-responders (>18 months) group
| ICs | All Nivolumab pts N = 21 |
Long-responders pts (PFS>18mo) N = 9 |
p value * |
|---|---|---|---|
| sPD-1 Median (ng/ml) Range |
2.00 0.52–25.00 |
13.25 1.22–25.00 |
p = .01 |
| sPD-L1 Median (ng/ml) Range |
0.64 0.26–1.31 |
1.09 0.47–2.41 |
p = .02 |
| sBTN3g Median (ng/ml) Range |
12.94 3.32–28.18 |
12.32 7.79–27.77 |
p = ns |
| sBTN3A1 Median (ng/ml) Range |
6.84 2.03–24.76 |
11.03 5.11–24.76 |
p = .03 |
| sBTN2A1 Median (ng/ml) Range |
8.79 5.67–16.93 |
7.71 4.91–10.00 |
p = ns |
*ANOVA test